Cargando…

Clinical, electrocardiographic, and echocardiographic parameters associated with the development of pacing and implantable cardioverter-defibrillator indication in patients with transthyretin amyloid cardiomyopathy

AIMS: This study aimed to identify factors for attention leading to future pacing device implantation (PDI) and reveal the necessity of prophylactic PDI or implantable cardioverter-defibrillator (ICD) implantation in transthyretin amyloid cardiomyopathy (ATTR-CM) patients. METHODS AND RESULTS: This...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawahara, Yusei, Kanazawa, Hisanori, Takashio, Seiji, Tsuruta, Yuichiro, Sumi, Hitoshi, Kiyama, Takuya, Kaneko, Shozo, Ito, Miwa, Hoshiyama, Tadashi, Hirakawa, Kyoko, Ishii, Masanobu, Tabata, Noriaki, Yamanaga, Kenshi, Fujisue, Koichiro, Hanatani, Shinsuke, Sueta, Daisuke, Arima, Yuichiro, Araki, Satoshi, Usuku, Hiroki, Nakamura, Taishi, Yamamoto, Eiichiro, Soejima, Hirofumi, Matsushita, Kenichi, Kawano, Hiroaki, Tsujita, Kenichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10228612/
https://www.ncbi.nlm.nih.gov/pubmed/37099643
http://dx.doi.org/10.1093/europace/euad105
_version_ 1785051002042318848
author Kawahara, Yusei
Kanazawa, Hisanori
Takashio, Seiji
Tsuruta, Yuichiro
Sumi, Hitoshi
Kiyama, Takuya
Kaneko, Shozo
Ito, Miwa
Hoshiyama, Tadashi
Hirakawa, Kyoko
Ishii, Masanobu
Tabata, Noriaki
Yamanaga, Kenshi
Fujisue, Koichiro
Hanatani, Shinsuke
Sueta, Daisuke
Arima, Yuichiro
Araki, Satoshi
Usuku, Hiroki
Nakamura, Taishi
Yamamoto, Eiichiro
Soejima, Hirofumi
Matsushita, Kenichi
Kawano, Hiroaki
Tsujita, Kenichi
author_facet Kawahara, Yusei
Kanazawa, Hisanori
Takashio, Seiji
Tsuruta, Yuichiro
Sumi, Hitoshi
Kiyama, Takuya
Kaneko, Shozo
Ito, Miwa
Hoshiyama, Tadashi
Hirakawa, Kyoko
Ishii, Masanobu
Tabata, Noriaki
Yamanaga, Kenshi
Fujisue, Koichiro
Hanatani, Shinsuke
Sueta, Daisuke
Arima, Yuichiro
Araki, Satoshi
Usuku, Hiroki
Nakamura, Taishi
Yamamoto, Eiichiro
Soejima, Hirofumi
Matsushita, Kenichi
Kawano, Hiroaki
Tsujita, Kenichi
author_sort Kawahara, Yusei
collection PubMed
description AIMS: This study aimed to identify factors for attention leading to future pacing device implantation (PDI) and reveal the necessity of prophylactic PDI or implantable cardioverter-defibrillator (ICD) implantation in transthyretin amyloid cardiomyopathy (ATTR-CM) patients. METHODS AND RESULTS: This retrospective single-center observational study included consecutive 114 wild-type ATTR-CM (ATTRwt-CM) and 50 hereditary ATTR-CM (ATTRv-CM) patients, neither implanted with a pacing device nor fulfilling indications for PDI at diagnosis. As a study outcome, patient backgrounds were compared with and without future PDI, and the incidence of PDI in each conduction disturbance was examined. Furthermore, appropriate ICD therapies were investigated in all 19 patients with ICD implantation. PR-interval ≥220 msec, interventricular septum (IVS) thickness ≥16.9 mm, and bifascicular block were significantly associated with future PDI in ATTRwt-CM patients, and brain natriuretic peptide ≥35.7 pg/mL, IVS thickness ≥11.3 mm, and bifascicular block in ATTRv-CM patients. The incidence of subsequent PDI in patients with bifascicular block at diagnosis was significantly higher than that of normal atrioventricular (AV) conduction in both ATTRwt-CM [hazard ratio (HR): 13.70, P = 0.019] and ATTRv-CM (HR: 12.94, P = 0.002), whereas that of patients with first-degree AV block was neither (ATTRwt-CM: HR: 2.14, P = 0.511, ATTRv-CM: HR: 1.57, P = 0.701). Regarding ICD, only 2 of 16 ATTRwt-CM and 1 of 3 ATTRv-CM patients received appropriate anti-tachycardia pacing or shock therapy, under the number of intervals to detect for ventricular tachycardia of 16–32. CONCLUSIONS: According to our retrospective single-center observational study, prophylactic PDI did not require first-degree AV block in both ATTRwt-CM and ATTRv-CM patients, and prophylactic ICD implantation was also controversial in both ATTR-CM. Larger prospective, multi-center studies are necessary to confirm these results.
format Online
Article
Text
id pubmed-10228612
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-102286122023-05-31 Clinical, electrocardiographic, and echocardiographic parameters associated with the development of pacing and implantable cardioverter-defibrillator indication in patients with transthyretin amyloid cardiomyopathy Kawahara, Yusei Kanazawa, Hisanori Takashio, Seiji Tsuruta, Yuichiro Sumi, Hitoshi Kiyama, Takuya Kaneko, Shozo Ito, Miwa Hoshiyama, Tadashi Hirakawa, Kyoko Ishii, Masanobu Tabata, Noriaki Yamanaga, Kenshi Fujisue, Koichiro Hanatani, Shinsuke Sueta, Daisuke Arima, Yuichiro Araki, Satoshi Usuku, Hiroki Nakamura, Taishi Yamamoto, Eiichiro Soejima, Hirofumi Matsushita, Kenichi Kawano, Hiroaki Tsujita, Kenichi Europace Clinical Research AIMS: This study aimed to identify factors for attention leading to future pacing device implantation (PDI) and reveal the necessity of prophylactic PDI or implantable cardioverter-defibrillator (ICD) implantation in transthyretin amyloid cardiomyopathy (ATTR-CM) patients. METHODS AND RESULTS: This retrospective single-center observational study included consecutive 114 wild-type ATTR-CM (ATTRwt-CM) and 50 hereditary ATTR-CM (ATTRv-CM) patients, neither implanted with a pacing device nor fulfilling indications for PDI at diagnosis. As a study outcome, patient backgrounds were compared with and without future PDI, and the incidence of PDI in each conduction disturbance was examined. Furthermore, appropriate ICD therapies were investigated in all 19 patients with ICD implantation. PR-interval ≥220 msec, interventricular septum (IVS) thickness ≥16.9 mm, and bifascicular block were significantly associated with future PDI in ATTRwt-CM patients, and brain natriuretic peptide ≥35.7 pg/mL, IVS thickness ≥11.3 mm, and bifascicular block in ATTRv-CM patients. The incidence of subsequent PDI in patients with bifascicular block at diagnosis was significantly higher than that of normal atrioventricular (AV) conduction in both ATTRwt-CM [hazard ratio (HR): 13.70, P = 0.019] and ATTRv-CM (HR: 12.94, P = 0.002), whereas that of patients with first-degree AV block was neither (ATTRwt-CM: HR: 2.14, P = 0.511, ATTRv-CM: HR: 1.57, P = 0.701). Regarding ICD, only 2 of 16 ATTRwt-CM and 1 of 3 ATTRv-CM patients received appropriate anti-tachycardia pacing or shock therapy, under the number of intervals to detect for ventricular tachycardia of 16–32. CONCLUSIONS: According to our retrospective single-center observational study, prophylactic PDI did not require first-degree AV block in both ATTRwt-CM and ATTRv-CM patients, and prophylactic ICD implantation was also controversial in both ATTR-CM. Larger prospective, multi-center studies are necessary to confirm these results. Oxford University Press 2023-04-26 /pmc/articles/PMC10228612/ /pubmed/37099643 http://dx.doi.org/10.1093/europace/euad105 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Clinical Research
Kawahara, Yusei
Kanazawa, Hisanori
Takashio, Seiji
Tsuruta, Yuichiro
Sumi, Hitoshi
Kiyama, Takuya
Kaneko, Shozo
Ito, Miwa
Hoshiyama, Tadashi
Hirakawa, Kyoko
Ishii, Masanobu
Tabata, Noriaki
Yamanaga, Kenshi
Fujisue, Koichiro
Hanatani, Shinsuke
Sueta, Daisuke
Arima, Yuichiro
Araki, Satoshi
Usuku, Hiroki
Nakamura, Taishi
Yamamoto, Eiichiro
Soejima, Hirofumi
Matsushita, Kenichi
Kawano, Hiroaki
Tsujita, Kenichi
Clinical, electrocardiographic, and echocardiographic parameters associated with the development of pacing and implantable cardioverter-defibrillator indication in patients with transthyretin amyloid cardiomyopathy
title Clinical, electrocardiographic, and echocardiographic parameters associated with the development of pacing and implantable cardioverter-defibrillator indication in patients with transthyretin amyloid cardiomyopathy
title_full Clinical, electrocardiographic, and echocardiographic parameters associated with the development of pacing and implantable cardioverter-defibrillator indication in patients with transthyretin amyloid cardiomyopathy
title_fullStr Clinical, electrocardiographic, and echocardiographic parameters associated with the development of pacing and implantable cardioverter-defibrillator indication in patients with transthyretin amyloid cardiomyopathy
title_full_unstemmed Clinical, electrocardiographic, and echocardiographic parameters associated with the development of pacing and implantable cardioverter-defibrillator indication in patients with transthyretin amyloid cardiomyopathy
title_short Clinical, electrocardiographic, and echocardiographic parameters associated with the development of pacing and implantable cardioverter-defibrillator indication in patients with transthyretin amyloid cardiomyopathy
title_sort clinical, electrocardiographic, and echocardiographic parameters associated with the development of pacing and implantable cardioverter-defibrillator indication in patients with transthyretin amyloid cardiomyopathy
topic Clinical Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10228612/
https://www.ncbi.nlm.nih.gov/pubmed/37099643
http://dx.doi.org/10.1093/europace/euad105
work_keys_str_mv AT kawaharayusei clinicalelectrocardiographicandechocardiographicparametersassociatedwiththedevelopmentofpacingandimplantablecardioverterdefibrillatorindicationinpatientswithtransthyretinamyloidcardiomyopathy
AT kanazawahisanori clinicalelectrocardiographicandechocardiographicparametersassociatedwiththedevelopmentofpacingandimplantablecardioverterdefibrillatorindicationinpatientswithtransthyretinamyloidcardiomyopathy
AT takashioseiji clinicalelectrocardiographicandechocardiographicparametersassociatedwiththedevelopmentofpacingandimplantablecardioverterdefibrillatorindicationinpatientswithtransthyretinamyloidcardiomyopathy
AT tsurutayuichiro clinicalelectrocardiographicandechocardiographicparametersassociatedwiththedevelopmentofpacingandimplantablecardioverterdefibrillatorindicationinpatientswithtransthyretinamyloidcardiomyopathy
AT sumihitoshi clinicalelectrocardiographicandechocardiographicparametersassociatedwiththedevelopmentofpacingandimplantablecardioverterdefibrillatorindicationinpatientswithtransthyretinamyloidcardiomyopathy
AT kiyamatakuya clinicalelectrocardiographicandechocardiographicparametersassociatedwiththedevelopmentofpacingandimplantablecardioverterdefibrillatorindicationinpatientswithtransthyretinamyloidcardiomyopathy
AT kanekoshozo clinicalelectrocardiographicandechocardiographicparametersassociatedwiththedevelopmentofpacingandimplantablecardioverterdefibrillatorindicationinpatientswithtransthyretinamyloidcardiomyopathy
AT itomiwa clinicalelectrocardiographicandechocardiographicparametersassociatedwiththedevelopmentofpacingandimplantablecardioverterdefibrillatorindicationinpatientswithtransthyretinamyloidcardiomyopathy
AT hoshiyamatadashi clinicalelectrocardiographicandechocardiographicparametersassociatedwiththedevelopmentofpacingandimplantablecardioverterdefibrillatorindicationinpatientswithtransthyretinamyloidcardiomyopathy
AT hirakawakyoko clinicalelectrocardiographicandechocardiographicparametersassociatedwiththedevelopmentofpacingandimplantablecardioverterdefibrillatorindicationinpatientswithtransthyretinamyloidcardiomyopathy
AT ishiimasanobu clinicalelectrocardiographicandechocardiographicparametersassociatedwiththedevelopmentofpacingandimplantablecardioverterdefibrillatorindicationinpatientswithtransthyretinamyloidcardiomyopathy
AT tabatanoriaki clinicalelectrocardiographicandechocardiographicparametersassociatedwiththedevelopmentofpacingandimplantablecardioverterdefibrillatorindicationinpatientswithtransthyretinamyloidcardiomyopathy
AT yamanagakenshi clinicalelectrocardiographicandechocardiographicparametersassociatedwiththedevelopmentofpacingandimplantablecardioverterdefibrillatorindicationinpatientswithtransthyretinamyloidcardiomyopathy
AT fujisuekoichiro clinicalelectrocardiographicandechocardiographicparametersassociatedwiththedevelopmentofpacingandimplantablecardioverterdefibrillatorindicationinpatientswithtransthyretinamyloidcardiomyopathy
AT hanatanishinsuke clinicalelectrocardiographicandechocardiographicparametersassociatedwiththedevelopmentofpacingandimplantablecardioverterdefibrillatorindicationinpatientswithtransthyretinamyloidcardiomyopathy
AT suetadaisuke clinicalelectrocardiographicandechocardiographicparametersassociatedwiththedevelopmentofpacingandimplantablecardioverterdefibrillatorindicationinpatientswithtransthyretinamyloidcardiomyopathy
AT arimayuichiro clinicalelectrocardiographicandechocardiographicparametersassociatedwiththedevelopmentofpacingandimplantablecardioverterdefibrillatorindicationinpatientswithtransthyretinamyloidcardiomyopathy
AT arakisatoshi clinicalelectrocardiographicandechocardiographicparametersassociatedwiththedevelopmentofpacingandimplantablecardioverterdefibrillatorindicationinpatientswithtransthyretinamyloidcardiomyopathy
AT usukuhiroki clinicalelectrocardiographicandechocardiographicparametersassociatedwiththedevelopmentofpacingandimplantablecardioverterdefibrillatorindicationinpatientswithtransthyretinamyloidcardiomyopathy
AT nakamurataishi clinicalelectrocardiographicandechocardiographicparametersassociatedwiththedevelopmentofpacingandimplantablecardioverterdefibrillatorindicationinpatientswithtransthyretinamyloidcardiomyopathy
AT yamamotoeiichiro clinicalelectrocardiographicandechocardiographicparametersassociatedwiththedevelopmentofpacingandimplantablecardioverterdefibrillatorindicationinpatientswithtransthyretinamyloidcardiomyopathy
AT soejimahirofumi clinicalelectrocardiographicandechocardiographicparametersassociatedwiththedevelopmentofpacingandimplantablecardioverterdefibrillatorindicationinpatientswithtransthyretinamyloidcardiomyopathy
AT matsushitakenichi clinicalelectrocardiographicandechocardiographicparametersassociatedwiththedevelopmentofpacingandimplantablecardioverterdefibrillatorindicationinpatientswithtransthyretinamyloidcardiomyopathy
AT kawanohiroaki clinicalelectrocardiographicandechocardiographicparametersassociatedwiththedevelopmentofpacingandimplantablecardioverterdefibrillatorindicationinpatientswithtransthyretinamyloidcardiomyopathy
AT tsujitakenichi clinicalelectrocardiographicandechocardiographicparametersassociatedwiththedevelopmentofpacingandimplantablecardioverterdefibrillatorindicationinpatientswithtransthyretinamyloidcardiomyopathy